Extracorporeal Membrane Oxygenation (ECMO)

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University300 enrolled

Overview

Since the 1970s, extracorporeal membrane oxygenation (ECMO) support has been used to support gas exchange for children with severe acute respiratory failure who fail mechanical ventilation. ECMO is more expensive than each of these other procedures.But its action is unclear

Since 1974, eight randomized controlled trials have been reported in ECMO for respiratory failure, and none have included non-neonatal pediatric patients. Cochrane systematic reviews of this evidence concluded that ECMO for neonatal respiratory failure had a survival advantage, but there was insufficient evidence to demonstrate a survival advantage for ECMO used to support respiratory failure in adults. Moreover, these trials were performed prior to 2009, and since then advances in ECMO technology have enhanced the delivery of ECMO support, and new research has changed conventional management of severe acute respiratory distress syndrome (ARDS)

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Extracorporeal Membrane Oxygenation

Interventions

ECMODEVICE

the patients with severe respiratory failure were supported by ECMO

conventional mechanical ventilationDEVICE

the patients with severe respiratory failure were supported by conventional mechanical ventilation

Eligibility

Sex: ALLMin age: 1 HourMax age: 1 Month

Medical Language ↔ Plain English

Inclusion Criteria: 1\. ECMO group: 1. Oxygenation Index \> 40 for \>4 hours 2. Failure to wean from 100% oxygen despite prolonged (\> 48h) maximal medical therapy or persistent episodes of decompensation 3. Severe hypoxic respiratory failure with acute decompensation (PaO2 \<40) unresponsive to intervention 4. Severe pulmonary hypertension with evidence of right ventricular dysfunction and/or left ventricular dysfunction. The pulmonary artery pressure \> 60mmHg evaluated by the Echo, arterial duct keeps open and the blood flow was either by-level shunt or completely shunt from right side to left side. 2\. Non-ECMO group: 1. Oxygenation Index \> 16 and reach the Montreux definition of severe respiratory distress syndrome 2. Vasoactive-inotropic score (VIS) ≥ 40 \[VIS=dopamine dose (μg/kg/min)×1 + dobutamine dose (μg/kg/min)×1 + milrinone dose (μg/kg/min)×10 + amrinone dose (μg/kg/min)×10 + epinephrine dose (μg/kg/min)×100 + isoprenaline dose (μg/kg/min)×100\] Exclusion Criteria: 1. Gestational age \< 36 weeks, birth weight \< 2 kg, day post-birth \> 28 days. 2. lethal chromosomal disorder (includes trisomy 13, 18 but not 21) or any other lethal anomaly 3. irreversible brain damage 4. uncontrolled bleeding 5. Grade III or greater intraventricular hemorrhage 6. ventilator days ≥ 15 days.

Locations (1)

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Chongqing, Chongqing Municipality, China

Outcomes

Primary Outcomes

in-hospital mortality

the patients died

Time frame: 36 weeks' gestational age or before discharge from hospital

28 days' mortality

the patients died

Time frame: 28 days

Secondary Outcomes

Neonatal necrotizing enterocolitis

Neonatal necrotizing enterocolitis was diagnosed after extubation

Time frame: 36 weeks' gestational age or before discharge from hospital

Intraventricular hemorrhage

Intraventricular hemorrhage was diagnosed after extubation

Time frame: 36 weeks' gestational age or before discharge from hospital

bronchopulmonary dysplasia

bronchopulmonary dysplasia was diagnosed after extubation

Time frame: 36 weeks' gestational age or before discharge from hospital

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.